Content: cookies-message

We use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits. If you continue browsing the website, you accept its installation and use as aforementioned. You may modify the settings and obtain more information here

Content: investors-link

Show menu Close

Company Commitment Innovation Team Products and services

Investors Careers Media Contact

Content: intro-company

Company

Since 1909, Grifols has worked to improve the health and well-being of people around the world.

Our business is organized into four divisions: Bioscience, Diagnostic, Hospital and Bio Supplies.

Mission

Our values

Divisions

Bioscience

From donors to patients
Plasma journey

Diagnostic
Hospital
Bio Supplies

History

Grifols museum

La Casa: where it all began
The Plant: people helping people
The World: From family business to global company

Grifology

Content: covid-19-destacado-1

Latest updates on COVID-19

Content: company-destacado-1

We improve the health and well-being of patients around the world.

Content: company-destacado-2

Four business divisions united by a shared commitment to quality, safety and on-going innovation.

Content: intro-commitment

Commitment

We are committed to a long-term vision that creates a sustainable, positive impact on the communities in which we operate.

Commitment to patients

Grifols Hemophilia Awareness
Global Awards

Eligibility Criteria
How to apply
Award Recipients
Contact

Commitment to science

Ethics and compliance

The environment

Foundations

Content: covid-19-destacado-1

Latest updates on COVID-19

Content: commitment-destacado-1

Patients inspire the work we do every day.

Content: commitment-destacado-2

We support the development of the scientific community and its research efforts.

Content: intro-innovation

Innovation

Since the foundation of Grifols, our on-going innovation has helped shape industry standards in the plasma medicines sector.

Research areas

COVID-19 Updates

Pipeline

AMBAR

Alzheimer's disease
Grifols and Alzheimer’s
The AMBAR hypothesis
The AMBAR study
The results
AMBAR in the Media

Content: covid-19-destacado-1

Latest updates on COVID-19

Content: innovation-destacado-1

Take a look at the portfolio of products and therapies currently in development.

Content: innovation-destacado-2

AMBAR, check latest results on Grifols' lead project on Alzheimer's.

Content: intro-team

Team

The efforts of every member of the Grifols team enable us to achieve our mission of improving people's health and well-being.

Grifols culture

Global footprint

Training and development

Content: covid-19-destacado-1

Latest updates on COVID-19

Content: team-destacado-1

We strive to cultivate a friendly, diverse and inclusive work environment.

Content: team-destacado-2

Grifols is becoming increasingly global. A diverse team will remain a key component to our future success.

Content: intro-investors

Investors

Financials

Quarterly reports
Annual accounts
CNMV communications
SEC communications
Fixed income and credit ratings
Average period of payment to suppliers

Inside Information

Other Relevant Information

Relevant events
up to December 31^st, 2019

Agenda

Press releases

Corporate governance

Board of Directors

Committees
Regulations

General Shareholders’ Meeting
Annual corporate governance report
Directors' remuneration report
Articles of association
Corporate policies

Corporate Stewardship

Presentations

Stock information

Stock and share capital

Class A shares
Class B shares
ADR program

· ADR Level I
· ADR Level III

Dividends
Agreements between shareholders
Major holders and treasury stock

Content: intro-careers

Careers

People are at the heart of our business. We are committed to continued investment in training and development.

Content: intro-media

Media

Latest news about the company and contact information for journalists and communication professionals.

Media contacts

Newsroom

Company Statements

Content: intro-contact

Contact

Headquartered in Barcelona, Spain, Grifols has more than 24,000 employees in 30 countries and regions. Contact us around the world.

International Headquarters

Adverse reactions – Pharmacovigilance

Show menu

Company Commitment Innovation Team Products and services

Investors Careers Media Contact

Spanish

English

Content: footer-content-logos

BACK

Company Mission Our values Divisions History Grifols museum Grifology

Spanish

English

Content: footer-content-logos

BACK

Divisions Bioscience Diagnostic Hospital Bio Supplies

Spanish

English

Content: footer-content-logos

BACK

Grifols museum La Casa: where it all began The Plant: people helping people The World: From family business to global company

Spanish

English

Content: footer-content-logos

BACK

Commitment Commitment to patients Commitment to science Ethics and compliance The environment Foundations

Spanish

English

Content: footer-content-logos

BACK

Commitment to patients Grifols Hemophilia Awareness Global Awards

Spanish

English

Content: footer-content-logos

BACK

Innovation Research areas COVID-19 Updates Pipeline AMBAR

Spanish

English

Content: footer-content-logos

BACK

AMBAR Alzheimer's disease Grifols and Alzheimer’s The AMBAR hypothesis The AMBAR study The results AMBAR in the Media

Spanish

English

Content: footer-content-logos

BACK

Team Grifols culture Global footprint Training and development

Spanish

English

Content: footer-content-logos

BACK

Products and services

Spanish

English

Content: footer-content-logos

BACK

Investors Financials Inside Information Other Relevant Information Relevant events up to December 31 st , 2019 Agenda Press releases Corporate governance Corporate Stewardship Presentations Stock information

Spanish

English

Content: footer-content-logos

BACK

Financials Quarterly reports Annual accounts CNMV communications SEC communications Fixed income and credit ratings Average period of payment to suppliers

Spanish

English

Content: footer-content-logos

BACK

Corporate governance Board of Directors General Shareholders’ Meeting Annual corporate governance report Directors' remuneration report Articles of association Corporate policies

Spanish

English

Content: footer-content-logos

BACK

Stock information Stock and share capital Dividends Agreements between shareholders Major holders and treasury stock

Spanish

English

Content: footer-content-logos

BACK

Careers

Spanish

English

Content: footer-content-logos

BACK

Media Media contacts Newsroom Company Statements

Spanish

English

Content: footer-content-logos

BACK

Contact International Headquarters Adverse reactions – Pharmacovigilance

Spanish

English

Content: footer-content-logos

MEDIA

Grifols reinforces its liquidity position to EUR 1,700 million

May 7, 2020

Grifols Procleix Panther System with Automation Ready Technology (ART) receives FDA Approval

May 5, 2020

Grifols completes development of very high sensitivity molecular test to detect SARS-CoV-2 virus

Show more news

Media contacts

Journalist or media professional?

Our Media Relations team is available at:
(+34) 93 571 00 02
media@grifols.com.
Restricted to media inquiries only.

Not a journalist?

For general questions and requests, please contact corporatecomms@grifols.com.

AMBAR

AMBAR in the Media

Press releases about AMBAR clinical trial and media coverage.

Content: footer-organization-info

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.

Content: footer-content-logos

Content: copyright

Content: footer-content-links-1

ABOUT US

Content: footer-content-links-2

TOP WEBSITES

Grifols Plasma

Grifols Academy

Grifols Scientific Awards

Grifols Engineering

Fundación Grifols

Fundación Probitas

Content: footer-content-links-3-sense-site-map

HELP

Privacy notices

Cookies policy

Contact

Content: copyright

Content: grifols-welcome-popup

Discover our new corporate site

Do you want to know more about one of the leading healthcare companies? Here you will find all the information about Grifols and our commitment to improving the health and well-being of people around world.

Enter

Content: hcp-products-popup

This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.

Are you a healthcare professional?

Yes